Overview

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral suspension

Phase:

Phase 1

Details

Lead Sponsor:

Seaside Therapeutics, Inc.

Collaborator:

National Institutes of Health (NIH)